[go: up one dir, main page]

NO20083640L - Antistoff-formulering - Google Patents

Antistoff-formulering

Info

Publication number
NO20083640L
NO20083640L NO20083640A NO20083640A NO20083640L NO 20083640 L NO20083640 L NO 20083640L NO 20083640 A NO20083640 A NO 20083640A NO 20083640 A NO20083640 A NO 20083640A NO 20083640 L NO20083640 L NO 20083640L
Authority
NO
Norway
Prior art keywords
antibodies
formulations
freeze
stabilizing
vegfr
Prior art date
Application number
NO20083640A
Other languages
English (en)
Inventor
Joel Goldstein
Arvind Srivastava
Original Assignee
Imclone Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Systems Inc filed Critical Imclone Systems Inc
Publication of NO20083640L publication Critical patent/NO20083640L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Sammendrag Den foreliggende oppfinnelse tilveiebringer formuleringer og fremgangsmåter for stabilisering av antistoffer. I én utførelsesfonn tilveiebringer oppfinnelsen den stabile formuleringen av antistoffer som er utsatt for ikke-enzymatisk fragmentering ved hengselregionen. I én ytterligere utførelsesfonn tilveiebringer oppfinnelsen fremgangsmåter for stabilisering av antistoffer som omfatter frysetørking av en vandig formulering av et antistoff. Formuleringene kan frysetørkes for å stabilisere antistoffene under prosessering og lagring, og formuleringene kan så rekondisjoneres for farmasøytisk administrering. I én utførelsesfonn tilveiebringer den foreliggende oppfinnelse fremgangsmåter for å stabilisere anti-VEGFR-antistoffer som omfatter frysetørking av en vandig formulering av et anti-VEGFR-antistoff. Formuleringene kan frysetørkes for å stabilisere anti-VEGFR-antistoffene under prosessering og lagring, og formuleringene kan så rekondisjoneres for farmasøytisk administrering.
NO20083640A 2006-02-15 2008-08-22 Antistoff-formulering NO20083640L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77410106P 2006-02-15 2006-02-15
PCT/US2007/004050 WO2007095337A2 (en) 2006-02-15 2007-02-15 Antibody formulation

Publications (1)

Publication Number Publication Date
NO20083640L true NO20083640L (no) 2008-11-17

Family

ID=38372139

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083640A NO20083640L (no) 2006-02-15 2008-08-22 Antistoff-formulering

Country Status (13)

Country Link
US (1) US20090306348A1 (no)
EP (1) EP1987067A4 (no)
JP (1) JP2009526856A (no)
KR (1) KR20080096827A (no)
CN (1) CN101495136A (no)
AU (1) AU2007215012A1 (no)
BR (1) BRPI0707796A2 (no)
CA (1) CA2642270A1 (no)
EA (1) EA200870264A1 (no)
IL (1) IL193408A0 (no)
MX (1) MX2008010562A (no)
NO (1) NO20083640L (no)
WO (1) WO2007095337A2 (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007260769A1 (en) * 2006-06-14 2007-12-21 Imclone Llc Lyophilized formulations of anti-EGFR antibodies
MX2009010361A (es) 2007-03-29 2009-10-16 Abbott Lab Anticuerpos il-12 anti-humanos cristalinos.
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CN105646643A (zh) 2008-10-29 2016-06-08 阿布林克斯公司 单域抗原结合性分子的纯化方法
BRPI0919979A2 (pt) * 2008-10-29 2015-12-15 Wyeth Llc formulações de moléculas de ligação de antígeno de domínio único
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
WO2011029823A1 (en) 2009-09-09 2011-03-17 Novartis Ag Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
EP2483301A1 (en) * 2009-10-01 2012-08-08 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
GB2490644A (en) 2010-03-31 2012-11-07 Stabilitech Ltd Excipients for stabilising viral particles, polypeptides or biological material
GB2499480A (en) * 2010-03-31 2013-08-21 Stabilitech Ltd Method for preserving alum adjuvants and alum-adjuvanted vaccines
DK2898890T3 (da) 2010-03-31 2019-11-25 Stabilitech Biopharma Ltd Stabilisering af viruspartikler
EP2625203A1 (en) 2010-10-05 2013-08-14 Novartis AG Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders
TWI486617B (zh) * 2010-10-21 2015-06-01 Iner Aec Executive Yuan 一種測定對鎝（Ｔｃ－９９ｍ）與錸（Ｒｅ－１８６、Ｒｅ－１８８）具有穩定錯合力之含硫螯合劑在凍晶劑中之含量與均一性的固態樣品分析技術
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
CA2856967A1 (en) * 2011-11-28 2013-06-06 Phasebio Pharmaceuticals, Inc. Therapeutic agents comprising insulin amino acid sequences
US9029510B2 (en) 2012-03-30 2015-05-12 Sorrento Therapeutics, Inc. Fully human antibodies that bind to VEGFR2 and methods of use thereof
CA2868883C (en) * 2012-03-30 2022-10-04 Sorrento Therapeutics Inc. Fully human antibodies that bind to vegfr2
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9193788B2 (en) 2013-02-08 2015-11-24 Novartis Ag Anti-IL-17A antibodies and their uses
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
US20170291939A1 (en) 2014-06-25 2017-10-12 Novartis Ag Antibodies specific for il-17a fused to hyaluronan binding peptide tags
JP2019500892A (ja) 2015-11-03 2019-01-17 ヤンセン バイオテツク，インコーポレーテツド Ｔｉｍ−３に特異的に結合する抗体及びその使用
MA43859A (fr) 2016-01-11 2018-11-21 Novartis Ag Anticorps monoclonaux humainisés immunostimulants dirigés contre l'interleukine -2 humaine, et leurs protéines de fusion
CN106188296B (zh) * 2016-07-19 2018-05-08 康融东方（广东）医药有限公司 一类抗血管内皮生长因子受体vegfr2的单克隆抗体及其编码基因和应用
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
US20200255496A1 (en) * 2017-09-18 2020-08-13 Amgen Inc. Vegfr-fc fusion protein formulations
US20190225689A1 (en) * 2018-01-22 2019-07-25 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-pd-1 antibodies
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
CN110646618B (zh) * 2019-09-17 2022-11-01 广州市伊川生物科技有限公司 一种c反应蛋白测定试剂盒及其制备方法和应用
US11773160B1 (en) 2022-08-05 2023-10-03 Anaveon AG Immune-stimulating IL-2 fusion proteins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IE64738B1 (en) * 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
US5270057A (en) * 1990-03-20 1993-12-14 Akzo N.V. Stabilized gonadotropin containing preparations
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
EP1409018B1 (en) * 2001-07-25 2010-01-06 Facet Biotech Corporation Stable lyophilized pharmaceutical formulation the igg antibody daclizumab
AU2003211990A1 (en) * 2002-02-14 2003-09-04 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution pharmaceuticals

Also Published As

Publication number Publication date
EP1987067A2 (en) 2008-11-05
US20090306348A1 (en) 2009-12-10
WO2007095337A2 (en) 2007-08-23
AU2007215012A1 (en) 2007-08-23
CA2642270A1 (en) 2007-08-23
MX2008010562A (es) 2009-03-05
CN101495136A (zh) 2009-07-29
BRPI0707796A2 (pt) 2011-05-10
IL193408A0 (en) 2011-08-01
EA200870264A1 (ru) 2009-02-27
WO2007095337A3 (en) 2008-11-27
KR20080096827A (ko) 2008-11-03
JP2009526856A (ja) 2009-07-23
EP1987067A4 (en) 2012-01-25

Similar Documents

Publication Publication Date Title
NO20083640L (no) Antistoff-formulering
WO2008116103A3 (en) Stable antibody formulations
CY1124703T1 (el) Μεθοδοι και συνθεσεις για παραδοση της ιδουρονικης-2-σουλφατασης στο κνς
AU2016204371A1 (en) Lyophilised and aqueous anti-CD40 antibody formulations
WO2012076670A3 (en) Antibody formulation
EP4249512A3 (en) Stable antibody formulation
WO2010100200A3 (en) Lyophilised antibody formulation
NO20064584L (no) Tetrahydropyridoindolderivater
PH12017500844A1 (en) Stable protein solution formulation containing high concentration of an anti-vegf antibody
TW200744665A (en) Vitamin E succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
MY159156A (en) Antibody formulation
WO2007047207A3 (en) 5-lipoxygenase-activating protein (flap) inhibitors
WO2008039218A3 (en) Inhibitors of bruton's tyrosine kinase
WO2007056021A3 (en) 5-lipoxygenase-activating protein (flap) inhibitors
WO2007056220A3 (en) 5-lipoxygenase-activating protein (flap) inhibitors
WO2007149406A3 (en) Modified coagulation factor ix polypeptides and use thereof for treatment
MX360435B (es) Formulaciones farmaceuticas muy concentradas.
NO20083104L (no) Fast preparat
WO2006089114A3 (en) Methods and compositions for treating an anthrax toxin mediated condition
EA201170036A1 (ru) Соединения боронатного эфира и его фармацевтические составы
BR112014021325A2 (pt) Formulação farmacêutica líquida e formulação liofilizada
EA201792487A1 (ru) Композиции гидроксипропил-бета-циклодекстринов и способы
WO2007067519A3 (en) The use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
WO2010078036A3 (en) Biocompatible polysaccharide-based hydrogels
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA, 0125 OSLO, NO

FC2A Withdrawal, rejection or dismissal of laid open patent application